Clinical Trial Update: BCMA/CD3 BsAb in the Treatment of High-risk Smoldering Multiple Myeloma [NA]

View source ↗

Summary

A clinical trial update indicates a BCMA/CD3 bispecific antibody is being studied for high-risk smoldering multiple myeloma, with the trial listed as not yet re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma
• Smoldering Multiple Myeloma

Drugs mentioned

• BCMA/CD3 BsAb (BCMA-CD3 bispecific antibody)

Snippet

Sponsor: Institute of Hematology & Blood Diseases Hospital, China | Conditions: High Risk Smoldering Multiple Myeloma | NA | Status: NOT_YET_RECRUITING